ADMA logo

ADMA
Adma Biologics Inc

20,410
Mkt Cap
$4.61B
Volume
2,319.00
52W High
$25.67
52W Low
$13.50
PE Ratio
22.61
ADMA Fundamentals
Price
$19.25
Prev Close
$19.38
Open
$19.43
50D MA
$15.63
Beta
1.27
Avg. Volume
4.02M
EPS (Annual)
$0.8123
P/B
10.64
Rev/Employee
$622,560.58
Loading...
Loading...
News
all
press releases
MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study
Mirum enrolls the first participant in its phase II BLOOM study investigating MRM-3379 for treating Fragile X syndrome.
Zacks·21h ago
News Placeholder
More News
News Placeholder
JNJ Gets EU Nod for Imaavy in Generalized Myasthenia Gravis
J&J gains EU approval for Imaavy, the first FcRn blocker for adults and adolescents with generalized myasthenia gravis.
Zacks·21h ago
News Placeholder
ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know
Arcturus Therapeutics' stock slides 59%, primarily due to mixed interim results from the phase II study of its investigational inhaled cystic fibrosis therapy, ARCT-032.
Zacks·2d ago
News Placeholder
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Zacks·2d ago
News Placeholder
Legal & General Group Plc Acquires 37,699 Shares of ADMA Biologics Inc $ADMA
Legal & General Group Plc raised its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 5.6% in the second quarter, according to the company in its most recent disclosure with...
MarketBeat·2d ago
News Placeholder
Ensign Peak Advisors Inc Acquires 80,462 Shares of ADMA Biologics Inc $ADMA
Ensign Peak Advisors Inc boosted its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 122.7% during the 2nd quarter, according to its most recent disclosure with the Securities...
MarketBeat·5d ago
News Placeholder
Wall Street Analysts Think Adma Biologics (ADMA) Could Surge 60.24%: Read This Before Placing a Bet
The consensus price target hints at a 60.2% upside potential for Adma Biologics (ADMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·6d ago
News Placeholder
Franklin Resources Inc. Boosts Stock Holdings in ADMA Biologics Inc $ADMA
Franklin Resources Inc. grew its position in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 66.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·6d ago
News Placeholder
American Century Companies Inc. Buys 358,627 Shares of ADMA Biologics Inc $ADMA
American Century Companies Inc. raised its stake in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 8.4% during the second quarter, according to its most recent filing with the Securities and...
MarketBeat·7d ago
News Placeholder
Adma Biologics (ADMA) Upgraded to Buy: Here's What You Should Know
Adma Biologics (ADMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·8d ago

Latest ADMA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.